Activates both GLP-1 and GIP receptors; the sponsor describes it as a biased receptor agonist.
Chinese adults with overweight or obesity without diabetes
Study contextPhase 3 obesity and diabetes trials fully enrolled.
Status sourceStatus & indications21.18% reported weight loss · 2.96% loss with placebo · 24 weeks
REBUILDING-1 · Phase 2 · sponsor · 18 mg every two weeks · Other / incompletely specified
Evidence & limitationsGI events mainly mild/moderate; no drug-related serious events.
Safety contextA next milestone is not summarized for this therapy.
Milestone detailsStudy results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
21.18% reported weight loss · 2.96% loss with placebo · 24 weeks
18 mg every two weeks
Chinese adults with overweight or obesity without diabetes
Least-squares mean change; public abstract does not specify formal estimand. Phase 3 obesity and diabetes trials fully enrolled.
GI events mainly mild/moderate; no drug-related serious events.
Limitations: Sponsor says243 enrolled; abstract reports231 participants. Arm count unavailable; conference result.
Status in this atlas: Phase 3 obesity and diabetes trials fully enrolled. Status source
Activates both GLP-1 and GIP receptors; the sponsor describes it as a biased receptor agonist.
No approved trade name verified as of September 13, 2026; the compound name and development codes are not trade names.
Guangdong Raynovent Biotech · Originator; retains intellectual property and leads clinical development and registration.; Guangdong Zhongsheng Pharmaceutical · Majority-owning parent of Raynovent.; Qilu Pharmaceutical · Manufacturing and commercialization licensee for Mainland China, Hong Kong, Macau and Taiwan.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Activates both GLP-1 and GIP receptors; the sponsor describes it as a biased receptor agonist.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
RAY1225RAY1225 · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
Raynovent announced completion of enrollment in its Chinese registrational obesity trial.
SourceRaynovent and Qilu signed a Greater-China licensing agreement; the company website posted the announcement in May.
SourceThe phase 2 study was presented with biweekly-dose weight-loss findings; the company posted its report June 8.
SourceSelected sources checked Sep 13, 2026. This is not an exhaustive history.